Shares of National Research Co. (NASDAQ:NRCIB) have earned an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.

Analysts have set a one year consensus target price of $44.00 for the company and are expecting that the company will post $0.27 earnings per share for the current quarter, according to Zacks. Zacks has also assigned National Research an industry rank of 117 out of 265 based on the ratings given to related companies.

Several hedge funds and other institutional investors have recently bought and sold shares of NRCIB. Dimensional Fund Advisors LP raised its stake in National Research by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 90,616 shares of the business services provider’s stock valued at $3,570,000 after purchasing an additional 457 shares during the period. Rice Hall James & Associates LLC raised its stake in National Research by 1.0% during the 2nd quarter. Rice Hall James & Associates LLC now owns 10,102 shares of the business services provider’s stock valued at $480,000 after purchasing an additional 104 shares during the period. Willis Investment Counsel raised its stake in National Research by 1.7% during the 2nd quarter. Willis Investment Counsel now owns 29,042 shares of the business services provider’s stock valued at $1,379,000 after purchasing an additional 490 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in National Research during the 3rd quarter valued at $215,000. Finally, Tudor Investment Corp ET AL acquired a new stake in National Research during the 2nd quarter valued at $243,000. 2.61% of the stock is currently owned by institutional investors.

National Research (NRCIB) traded down $0.11 on Monday, reaching $52.79. The company’s stock had a trading volume of 4,782 shares, compared to its average volume of 3,180. The firm has a market capitalization of $1,295.10, a P/E ratio of 74.51 and a beta of 0.07. National Research has a 12-month low of $38.50 and a 12-month high of $57.21.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 12th. Shareholders of record on Friday, December 29th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $2.40 annualized dividend and a dividend yield of 4.55%. National Research’s dividend payout ratio is currently 480.00%.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/11/zacks-analysts-set-44-00-price-target-for-national-research-co-nrcib.html.

National Research Company Profile

National Research Corporation provides analytics and insights for the patient and employee experience in serving the healthcare providers, payers, and other healthcare organizations in the United States and Canada. Its portfolio of subscription-based solutions offer information and analysis services in a range of elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Get a free copy of the Zacks research report on National Research (NRCIB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for National Research Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Co. and related companies with MarketBeat.com's FREE daily email newsletter.